Literature DB >> 20921566

Congenital hypotonia in a child with a de novo 22q13 monosomy and 2pter duplication: a clinical and molecular genetic study.

Antonio Trabacca1, Luciana Losito, Marta De Rinaldis, Leonarda Gennaro.   

Abstract

The authors describe a 5-year-old girl with a neurological phenotype of 22q13 deletion syndrome (neonatal and persisting hypotonia, developmental delay, absence of language, decreased perception of pain) and minor dysmorphisms. Subtelomeric fluorescent in situ hybridization tests revealed de novo 22q13 monosomy and 2pter duplication. Numerous genetic and neurologic disorders of childhood are characterized by congenital hypotonia. This muscle tone disorder is often one of the symptoms that a neurologist is asked to evaluate. Recent advances in genetic testing can help provide a specific diagnosis for children with this symptom. Subtelomeric deletions are a category of disorders of which hypotonia can be a prominent feature. Deletions of chromosome 22q13 are some of the most commonly observed terminal deletions in humans, whereas duplications of chromosome 2p25.2 are very rare, and little is known about the phenotypic effect of these duplications. To the best of the authors' knowledge, this association has never been described before.

Entities:  

Mesh:

Year:  2010        PMID: 20921566     DOI: 10.1177/0883073810381444

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  2 in total

Review 1.  A role for synaptic zinc in ProSAP/Shank PSD scaffold malformation in autism spectrum disorders.

Authors:  Andreas M Grabrucker
Journal:  Dev Neurobiol       Date:  2013-09-11       Impact factor: 3.964

Review 2.  Phelan-McDermid syndrome: a review of the literature and practice parameters for medical assessment and monitoring.

Authors:  Alexander Kolevzon; Benjamin Angarita; Lauren Bush; A Ting Wang; Yitzchak Frank; Amy Yang; Robert Rapaport; Jeffrey Saland; Shubhika Srivastava; Cristina Farrell; Lisa J Edelmann; Joseph D Buxbaum
Journal:  J Neurodev Disord       Date:  2014-10-08       Impact factor: 4.025

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.